全球肺部/呼吸道药物输送市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

肺部/呼吸道药物输送市场分析

肺部/呼吸道药物输送市场正在经历显著增长，这得益于哮喘和慢性阻塞性肺病(COPD) 等呼吸道疾病发病率的上升以及药物输送技术的进步。市场最近的创新包括智能吸入器的出现，它利用数字技术来改善药物依从性和患者治疗效果。此外，各公司正在投资研发新型配方和输送系统，包括雾化器和干粉吸入器，它们可以提高生物利用度并实现治疗的靶向输送。制药公司和技术公司之间的合作进一步加速了先进肺部药物输送系统的开发，例如旨在整合人工智能以实现个性化治疗计划的合作伙伴关系。随着新兴经济体意识的增强和医疗支出的增加，肺部/呼吸道药物输送市场有望实现大幅增长，为整个医疗保健领域的利益相关者提供丰厚的利润机会。

肺部/呼吸道药物输送市场规模

2023 年全球肺/呼吸道药物输送市场规模价值 601.3 亿美元，预计到 2031 年将达到 995.2 亿美元，2024 年至 2031 年预测期内的复合年增长率为 6.50%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

肺部/呼吸道药物输送市场趋势

“智能吸入器的普及率不断上升”

肺部/呼吸道药物输送市场正在经历大幅增长，这得益于哮喘和慢性阻塞性肺病 (COPD) 等呼吸道疾病的日益流行。市场的一个突出趋势是智能吸入器的采用率不断上升，智能吸入器集成了数字技术，可提高药物依从性和患者管理。例如，Propeller Health 等公司开发了配备传感器的吸入器，可跟踪药物使用情况并向患者和医疗保健提供者提供实时反馈，从而促进更好地管理呼吸系统疾病。这项创新使患者能够监测他们的药物摄入量，并帮助临床医生评估治疗效果。随着对有效呼吸疗法的需求不断增加，将先进技术整合到药物输送系统中预计将在改善患者预后、促进及时干预以及最终重塑肺部药物输送解决方案格局方面发挥关键作用。

报告范围和肺/呼吸道药物输送市场细分

Pulmonary/Respiratory Drug Delivery Market Definition

Pulmonary/respiratory drug delivery refers to the administration of therapeutic agents directly into the lungs via inhalation. This method allows for the rapid absorption of drugs through the pulmonary epithelium, enabling immediate effects, particularly for respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung infections. Various delivery devices are utilized in this process, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and smart inhalers, which often incorporate technology for enhanced medication adherence and monitoring.

Pulmonary/Respiratory Drug Delivery Market Dynamics

Drivers

• Rising Prevalence of Respiratory Diseases

The rising prevalence of respiratory diseases is a critical factor driving the demand for effective pulmonary drug delivery systems. Chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD) are becoming increasingly common, affecting millions of individuals worldwide. According to the World Health Organization (WHO), more than 400 million people globally suffer from asthma, highlighting the urgent need for innovative treatment options that ensure effective disease management. In addition, the growing recognition of asthma and COPD as significant public health challenges has prompted healthcare providers and policymakers to prioritize the development and accessibility of advanced pulmonary drug delivery systems. Consequently, driving the market expansion.

• Increasing Rate of Air Pollution

The increasing rate of air pollution is a significant driver of the pulmonary/respiratory drug delivery market, as it leads to a heightened risk of lung infections such as bronchitis and pneumonia. Polluted air can cause breathing difficulties and contribute to various severe lung issues. According to the World Health Organization (WHO), environmental air pollution is estimated to be responsible for approximately 16% of lung cancer deaths, around 17% of fatalities from ischemic heart disease and stroke, 25% of COPD deaths, and about 26% of respiratory infection-related deaths. Such alarming data underscores the urgent need for effective treatment options, which enhances the demand for pulmonary drug delivery systems. As air quality continues to decline, the market for innovative inhalation drug delivery is expected to expand, driven by the need for more effective respiratory treatments.

Opportunities

• Rising Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is playing a pivotal role in enhancing access to pulmonary drug delivery systems, particularly in emerging markets. For instance, according to the World Health Organization (WHO), healthcare spending in low- and middle-income countries is expected to increase significantly, with an estimated growth from $400 billion in 2020 to over $1 trillion by 2025. Such influx of capital is being directed towards upgrading healthcare facilities, improving diagnostic capabilities, and expanding the availability of essential medications, including advanced inhalation therapies. As a result, the expansion of healthcare infrastructure improves patient outcomes and create market growth opportunities for pulmonary drug delivery systems.

• Increasing Regulatory Support

Regulatory support plays a crucial role in fostering innovation within the pulmonary drug delivery market by streamlining the approval process for new products. For instance, the U.S. Food and Drug Administration (FDA) has implemented various initiatives, such as the Breakthrough Devices Program, designed to expedite the development and review of medical devices that offer significant advantages over existing alternatives. In 2023, the FDA approved over many new pulmonary drug delivery devices, reflecting its commitment to facilitating faster access to innovative therapies. Such regulatory support encourages manufacturers to invest in research and development and fosters collaboration between regulatory bodies and industry stakeholders, ensuring that safe and effective pulmonary delivery systems reach patients more quickly. As regulatory frameworks continue to evolve, they will play an increasingly important role in creating opportunities in the market and advancing the availability of cutting-edge respiratory treatments.

Restraints/Challenges

• High Costs Associated with Research and Development

High costs associated with research and development (R&D) pose a significant challenge in the pulmonary drug delivery market, particularly for smaller companies and startups. Developing innovative pulmonary drug delivery systems requires substantial financial investment across various stages, including formulation development, preclinical studies, and extensive clinical trials to demonstrate safety and efficacy. Such financial barriers can hinder smaller firms from bringing their products to market, as they often lack the capital necessary to fund lengthy and expensive clinical trials. In addition, the competitive landscape, dominated by well-established pharmaceutical companies with ample resources, makes it increasingly difficult for new entrants to secure funding. Consequently, the high costs of R&D can limit innovation and reduce the availability of novel pulmonary drug delivery solutions that could greatly benefit patients.

• Limited Formulation Stability and Variabile Dosing Consistency

The pulmonary/respiratory drug delivery market faces significant challenges related to poor formulation stability for drugs and improper dosing reproducibility, which can adversely affect therapeutic outcomes. Many pulmonary formulations are sensitive to environmental factors such as humidity and temperature, leading to instability that compromises drug efficacy. In addition, improper dosing reproducibility remains a critical issue, as variability in inhaler techniques among patients can result in inconsistent delivery of medication. As a result, the challenges of poor formulation stability and improper dosing reproducibility significantly hinder the effectiveness of therapies in the pulmonary/respiratory drug delivery market, impacting patient outcomes and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pulmonary/Respiratory Drug Delivery Market Scope

The market is segmented on the basis of product, canister type, application, distribution channel, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Formulation Type
  • Suspension Aerosol
  • Solution Aerosol
  • Dry Powder Formulation
• Device Type
  • Metred Dose Inhalers(MDI)
  • Dry Powder Inhalers(DPI)
  • Nebulizers

Canister Type

• Plain Canisters
• Coated Canisters

Application

• Chronic Obstructive Pulmonary Disease
• Asthma
• Cystic Fibrosis

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• E-Commerce

End User

• Hospitals
• Clinics
• Home Care Settings

Pulmonary/Respiratory Drug Delivery Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, canister type, application, distribution channel, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a dominant position in the pulmonary and respiratory drug delivery market, primarily due to the presence of significant key players and the rising demand for advanced diagnostic devices such as pulmonary drug delivery systems (PDDS). The region also benefits from an increase in disposable income, which allows for greater investment in healthcare technologies. Furthermore, the surging incidence of various respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), is driving the need for effective drug delivery solutions, further solidifying North America's market leadership in this sector.

Asia-Pacific region is anticipated to experience substantial growth in the pulmonary and respiratory drug delivery market from 2024 to 2031, driven by the rising prevalence of asthma and allergic rhinitis among patients. In addition, an uptick in research and development activities in the region is fostering innovation and the introduction of new therapeutic options. Furthermore, heightened awareness campaigns initiated by public and private organizations are playing a crucial role in educating the population about respiratory health, thereby increasing demand for effective treatment solutions and contributing to the market's expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pulmonary/Respiratory Drug Delivery Market Share

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的肺部/呼吸道药物输送市场领导者是：

• 葛兰素史克公司 (英国)
• 勃林格殷格翰国际有限公司 (德国)
• 3M（美国）
• 阿斯利康（英国）
• 默克公司（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛默飞世尔科技公司（美国）
• 布鲁克 (美国)
• 雅培（美国）
• 诺华公司（瑞士）
• 克拉克国际（英国）
• Koninklijke Philips NV（荷兰）
• 欧姆龙株式会社（日本）
• Briggs Healthcare（英国）
• 住友制药美国公司（美国）

肺部/呼吸道药物输送市场的最新发展

• 2024 年 4 月，Launch Therapeutics, Inc. 和 Teva Pharmaceutical Industries Ltd. 宣布了一项临床合作协议，旨在加快 Teva 的 ICS-SABA (TEV-248) 的临床研究计划。此次合作旨在利用两家公司的专业知识来加强这种创新疗法的开发，该疗法将吸入性皮质类固醇与短效β受体激动剂相结合，以改善呼吸系统疾病的管理
• 2024 年 4 月，Nebu-Flow 成功获得额外 628 万美元的投资，以加快开发下一代吸入式药物，用于治疗呼吸系统疾病患者，呼吸系统疾病是全球死亡和残疾的主要原因。与现有技术相比，该公司的雾化器平台具有多项优势

SKU-25290